RecruitingPhase 1

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

United States42 participantsStarted 2021-12-01

Plain-language summary

This is a clinical trial for chronic pancreatitis (CP) patients undergoing total pancreatectomy with islet autotransplantation (TP-IAT). Participants will be randomized to either bone marrow-derived mesenchymal stem cells (MSCs) or control with the standard of care. Participants will be followed for one-year post-transplant.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of CP and scheduled for TP-IAT; * ≥18 years old; * Diabetes with HbA1c \<12%. Exclusion Criteria: * Patients who are under immunosuppression; * Pregnant and breastfeeding women. * Patients who have liver damage based on ALT, AST, and total bilirubin levels (\>3 times normal levels);

What they're measuring

Change in Islet Cell Function

Timeframe: 1 year

Trial details

NCT IDNCT05095532

SponsorMedical University of South Carolina

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06-30

Contact for this trial

Leah Benn, MPH

843-792-2813 bennle@musc.edu

View on ClinicalTrials.gov More Chronic Pancreatitis trials